Nelfinavir, a well known protease inhibitor indicated for the treatment of HIV infection, is proving to be of considerable value in maintaining sequencing options during antiretroviral therapy. A number of studies demonstrating the usefulness of this protease inhibitor were presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy [San Francisco, US; September 1999].